APPW2025

Oranizers :Satoshi Deyama (Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University) and Ryota Shinohara (Division of Pharmacology, Graduate School of Medicine, Kobe University)

Many stress-related disorders, including major depressive disorder and post-traumatic stress disorder (PTSD), are not adequately treated with currently available antidepressants and anxiolytics due to the complexity of their pathophysiology. Recently, considerable research and development efforts are being made to develop novel therapeutic agents based on mechanisms different from conventional monoaminergic antidepressants and benzodiazepine anxiolytics, as evidenced by clinical reports demonstrating the efficacy of the NMDA receptor antagonist ketamine in treatment-resistant depression and PTSD. In addition, studies on the mechanisms of stress resilience (resistance to and recovery from stress) have been actively conducted. This symposium aims to introduce and discuss novel therapeutic targets identified mainly through mouse studies focusing on the pathophysiology of stress-related disorders, the neural mechanisms of stress resilience, those underlying the effects of exercise on emotion, and the mechanisms of action of drug candidates.